Who Paid My Doc
Joyce Wu
Neurodevelopmental Disabilities Los Angeles, CA Medical Doctor
NPI 1831295138 CMS profile 729288
10833 Le Conte Avenue, 12-441 Mdcc, Los Angeles, CA 90095
General payments
$22,941
Research payments
$770
Ownership & investment interest
$0
Research they led as principal investigator
$291,085
Through program year 2025, Joyce Wu of Los Angeles, CA is reported in the CMS Open Payments database as having received $22,941 across 67 general payments and $770 in research payments paid to them. Separately, studies naming them as principal investigator received $291,085 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Neurodevelopmental Disabilities profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $96 | 1 | |
| 2024 | General | $118 | 5 | |
| 2023 | General | $3,672 | 8 | |
| 2022 | General | $4,868 | 14 | |
| 2021 | General | $2,938 | 8 | |
| 2020 | General | $1,578 | 2 | |
| 2019 | General | $9,672 | 29 | |
| 2019 | Research | $770 | 3 |
Beside peers
- Joyce Wu
- Neurodevelopmental Disabilities median
- Middle half of Neurodevelopmental Disabilities
- National median
In program year 2025, general payments to Joyce Wu were reported at $96. Among 64 Neurodevelopmental Disabilities profiles paid that year, the median was $136 and the middle half received between $67 and $819.
Show as a table
| Year | Joyce Wu | Neurodevelopmental Disabilities median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $9,672 | $138 | $34–$757 | $163 |
| 2020 | $1,578 | $63 | $23–$471 | $114 |
| 2021 | $2,938 | $158 | $43–$1,017 | $132 |
| 2022 | $4,868 | $225 | $76–$1,106 | $149 |
| 2023 | $3,672 | $228 | $73–$994 | $160 |
| 2024 | $118 | $167 | $57–$1,310 | $164 |
| 2025 | $96 | $136 | $67–$819 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
70 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurodevelopmental Disabilities in California
William Shields
Neurodevelopmental Disabilities · Los Angeles, CA
Raman Sankar
Neurodevelopmental Disabilities · Los Angeles, CA
Ying Peng
Neurodevelopmental Disabilities · Ladera Ranch, CA
Jason Lerner
Neurodevelopmental Disabilities · Los Angeles, CA
Elysa Marco
Neurodevelopmental Disabilities · San Francisco, CA
Christopher Giza
Neurodevelopmental Disabilities · Los Angeles, CA
Related records
Neurodevelopmental Disabilities in California
Practitioners in the same specialty and state, ranked by reported value.
All Neurodevelopmental Disabilities
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.